Moderna, Inc. share price logo

Moderna, Inc. Share Price

NASDAQ: MRNA

Large Cap

$50.81

-2.76

(-5.15%)

Live

as on

Moderna, Inc. Stock Performance

as on March 28, 2026 at 4:13 am IST

  • Day's Low

    Day's High

    $50.02
    $53.55
    downward going graph

    1.55%

    Downside

    5.39%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $22.28
    $59.55
    downward going graph

    56.15%

    Downside

    17.20%

    Upside

    downward going graph

Moderna, Inc. share price movements today

Previous Close
$53.57
Open
$53.29
Volume
4.8M
Day's Low - High
$50.02 - $53.55
52 Week Low - High
$22.28 - $59.55

Moderna, Inc. Historical Returns

1 Month Return
0 %
3 Month Return
+ 71.7 %
1 Year Return
+ 66.78 %
3 Year Return
-63.89 %
5 Year Return
-59.81 %

Moderna, Inc. Stock Fundamentals & Key Indicators

Check Moderna, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$21.2B

EPS (TTM)

-6.877

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.85%

PE Ratio (TTM)

-5.08

Industry PE ratio

17.836410256410257

PEG Ratio

0

EBITDA

-2.9B

Revenue (TTM)

1.9B

Profit Margin

-145.16%

Return On Equity TTM

-28.87%

Moderna, Inc. Stock Valuation

Track how Moderna, Inc. P/E has moved over time to understand its valuation trends.

Moderna, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-15.78x)

September 30, 2024

Today (-5.08x)

March 27, 2026

Industry (17.84x)

March 27, 2026

Highest (115.93x)

March 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -5.08x

Moderna, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Moderna, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Moderna, Inc. image
Moderna, Inc.
BUY$21.2B-59.81%-5.08-145.16%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.6B140.85%141.078.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.6B111.4%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.6BNA114.765.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$79.2B58.67%18.0831.41%

Stock Returns calculator for Moderna, Inc. Stock including INR - Dollar returns

The Moderna, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Moderna, Inc. investment value today

Current value as on today

₹1,68,697

Returns

₹68,697

(+68.7%)

Returns from Moderna, Inc. Stock

₹58,188 (+58.19%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Moderna, Inc. Stock

Based on 31 analysts

BUY

54.84%

Buy

35.48%

Hold

9.68%

Sell

Based on 31 analysts, 54.84% of analysts recommend a 'BUY' rating for Moderna, Inc.. Average target price of $43.75

Moderna, Inc. Share Price Target

Get share price movements and forecasts by analysts on Moderna, Inc..

What analysts predicted

-16.14%DOWNSIDE

Target Price

$43.75

Current Price

$50.81

Analyzed by

31 Analysts

Target

$43.75

Moderna, Inc. target price $43.75, a slight downside of -16.14% compared to current price of $50.81. According to 31 analysts rating.

Moderna, Inc. Stock’s Investor Sentiment and Interest

Investment in Moderna, Inc. Shares on INDmoney has dropped by -31.62% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-31.62% versus previous 30 day period

Search interest for Moderna, Inc. Stock has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-12% versus previous 30 day period

Moderna, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1,831
2,813
167
221
1,855
956
107
142
1,016
678
Gross Profit
-410
1,884
71
106
1,341
217
17
23
8
226
Operating Income
-2,012
6
-1,266
-1,363
-70
-1,246
-1,050
-907
-260
-857
EBITDA
-1,699
278
-1,123
-1,232
79
-1,118
-924
-760
-135
-732
Interest Expense
10
6
6
6
6
6
1
1
-
8
Depreciation
249
202
36
41
52
60
39
57
52
67
Income Before Tax
-1,958
70
-1,165
-1,279
21
-1,184
-964
-818
-187
-799
Income Tax Expense
1,672
-147
10
-
8
-64
7
7
13
27
Net Income
-3,630
217
-1,175
-1,279
13
-1,120
-971
-825
-200
-826
Net Profit Margin
-198.25%
7.71%
-703.59%
-578.73%
0.70%
-117.15%
-907.48%
-580.99%
-19.69%
-121.83%

Moderna, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
108
205
122
48
274
17,736
18,875
6,848
3,199
1,944
Gross Profit
93
185
-331
48
266
15,119
13,459
2,155
1,735
1,076
Operating Income
-223
-269
-413
-545
-763
13,296
9,420
-4,239
-3,945
-3,074
EBITDA
-208
-235
-388
-514
-731
13,528
9,768
-3,283
-3,394
-2,553
Interest Expense
-
0
3
6
9
18
29
38
24
10
Depreciation
-
20
24
31
31
232
348
499
189
215
Income Before Tax
-215
-255
-384
-514
-744
13,285
9,575
-3,942
-3,607
-2,768
Income Tax Expense
1
0
0
0
2
1,083
1,213
772
-46
54
Net Income
-216
-255
-384
-514
-747
12,202
8,362
-4,714
-3,561
-2,822
Net Profit Margin
-199.46%
-124.34%
-314.04%
-1070.07%
-272.16%
68.80%
44.30%
-68.84%
-111.32%
-145.16%

Moderna, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
217
-1,175
-1,279
13
-1,120
-971
-825
-200
-826
Operating Cash Flow
622
-989
-1,274
-1,566
825
-1,037
-919
-847
951
Investing Cash Flow
-538
118
1,649
721
-539
730
564
700
-48
Financing Cash Flow
-109
14
34
11
-3
4
9
-1
560
Change in Cash
-25
-857
409
-833
282
-303
-345
-147
1,462

Moderna, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-255
-384
-514
-747
12,202
8,362
-4,714
-3,561
-2,822
Operating Cash Flow
-331
-330
-458
2,026
13,620
4,981
-3,118
-3,004
-1,873
Investing Cash Flow
416
-372
-14
-1,671
-8,523
-5,176
4,206
1,949
1,946
Financing Cash Flow
0
1,226
51
2,033
-873
-3,448
-1,377
56
593
Change in Cash
84
523
-422
2,388
4,224
-3,643
-289
-999
668

Mutual Funds that own Moderna, Inc. Stock

Check out the Mutual Funds with significant holdings in Moderna, Inc..

Funds
Holdings
Shares Held
Motilal Oswal S&P 500 Index Fund Direct Growth
Motilal Oswal S&P 500 Index Fund Direct Growth
0.0313%
2603

Global Institutional Holdings in Moderna, Inc.

Funds
Holdings
Alyeska Investment Group, L.P.
0.82%
BlackRock Inc
7.48%
Baillie Gifford & Co Limited.
5.21%
Capital World Investors
3.25%
Theleme Partners LLP
2.05%
See all

Moderna, Inc. News & Key Events

    Insights on Moderna, Inc.

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 3 months, MRNA stock has moved up by 71.7%

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, MRNA has outperformed top 5 stocks with highest market-cap in its industry

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 136.2%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 1.01B → 678.0M (in $), with an average decrease of 33.3% per quarter

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, -200.0M → -826.0M (in $), with an average decrease of 313.0% per quarter

    About Moderna, Inc.

    "Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the "Moderna COVID-19 vaccine". The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna, Inc. has a market cap of $21.25 Billion. It has a P.E ratio of -5.08. The shares of Moderna, Inc. are trading at {current share price in dollars (in INR)}."
    OrganisationModerna, Inc.
    Headquarters325 Binney Street, Cambridge, MA, United States, 02142
    IndustryHealth Technology
    CEOMr. Stéphane Bancel M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Moderna, Inc.

    Name

    Title

    Ms. Tracey Franklin

    Chief People & Digital Technology Officer

    Mr. Patrick Norman Bergstedt

    Senior Vice President of Commercial Vaccines

    Mr. Stéphane Bancel M.B.A.

    CEO & Director

    Dr. Stephen Hoge M.D.

    President

    Ms. Shannon Thyme Klinger J.D.

    Chief Legal Officer & Corporate Secretary

    Dr. Jerh Collins Ph.D.

    Chief Technical Operations & Quality Officer

    Mr. James M. Mock

    Chief Financial Officer

    Ms. Lavina Talukdar CFA

    Senior VP & Head of Investor Relations

    Dr. Charbel Haber M.P.H., Ph.D.

    Senior VP & Head of Global Regulatory Science

    Dr. John Lepore J.D., M.D.

    Senior Vice President of Government Engagement

    FAQs

    What is Moderna, Inc. share price today?

    Moderna, Inc. share price today is $50.81 as on . Moderna, Inc. share today touched a day high of $53.55 and a low of $50.02.

    What is the 52 week high and 52 week low for Moderna, Inc. share?

    Moderna, Inc. share touched a 52 week high of $59.55 on and a 52 week low of $22.28 on . Moderna, Inc. stock price today i.e. is trending at $50.81,which is 14.68% down from its 52 week high and 128.05% up from its 52 week low.

    What is Moderna, Inc.'s market capitalisation today?

    Moderna, Inc. market capitalisation is $0.02T as on .

    How to invest in Moderna, Inc. Stock (MRNA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Moderna, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Moderna, Inc. Shares that will get you 0.0295 shares as per Moderna, Inc. share price of $50.81 per share as on March 27, 2026 at 10:43 pm IST.

    What is the minimum amount required to buy Moderna, Inc. Stock (MRNA) from India?

    Indian investors can start investing in Moderna, Inc. (MRNA) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹946.51 in Moderna, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Moderna, Inc. share’s latest price of $50.81 as on March 27, 2026 at 10:43 pm IST, you will get 0.1968 shares of Moderna, Inc.. Learn more about fractional shares .

    What are the returns that Moderna, Inc. has given to Indian investors in the last 5 years?

    Moderna, Inc. stock has given -59.81% share price returns and 29.26% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?